ClinicalTrials.gg
RecruitingNCT07015476Updated Jun 11, 2025

Retrospective Observational Evaluation of the Bone Mineral Density Outcome in Young Women With Amenorrhea

An observational study in Amenorrhea, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 1 site in Italy. Open to female participants aged 15 Years to 39 Years. Per ClinicalTrials.gov, last updated 2025-06-11.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
180
Ages
15 Years to 39 Years
Sex
Female
01

Study summary

The study aims to evaluate the outcomes of different estrogen therapy regimens in patients with amenorrhea who face prolonged periods of hypoestrogenism.

The primary objective is to compare the outcomes on bone mass of different therapeutic regimens and identify more favorable. For this purpose, densitometry parameters such as BMD, T-score and Z-score at the level of the lumbar spine, femur and entire skeleton will be considered, comparing a bone densitometry (DXA technique, Dual X-ray Absorptiometry) Baseline with one carried out after at least one year of therapy. The secondary objective of the study is to assess other systemic/metabolic implications of the different therapies.

Read the detailed description

The present retrospective monocentric observational study involves the recruitment of patients afferite at the U.O. of Gynecology and Physiopathology of Human Reproduction in the time interval between 2011 and 2020 in condition of amenorrhea greater than 6 months, Aged between 15 and 39 at the time of first visit.

Patients will be asked to participate in this study during the outpatient follow-up visit.

The study will involve data collection through consultation of health records.

The objectives of the study will therefore be achieved by analysing the following parameters, which can be fully deduced from the medical records of the subjects in the study:

  • Collection of anamnestic (eating habits and sports, pathologies of note, taking drugs, previous surgical interventions, smoking habit, gynecological history).
  • Physical examination: calculation of BMI, acne and hirsutism score (GAGS and Ferriman score), blood pressure measurement, gynecological physical examination
  • Transvaginal or transabdominal pelvic ultrasound
  • Lumbar, femoral, total body dual-energy x-ray absorptiometry (DXA)
  • Blood tests (blood count, lipid profile, glycemic, liver, kidney, hormonal status)
  • Reports of other visits and specialist examinations performed by the patients brought to view during the visit
02

Conditions studied

  • Amenorrhea

Browse trials for

Keywords

  • Amenorrhea
  • Bone Mass
  • Estrogen Therapy
03

In context

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

This study's planned enrollment of 180 is above the median of 85 across 26 observational studies indexed under Amenorrhea.

Browse Amenorrhea studies →

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 517 studies on the registry; 292 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The present retrospective observational study, monocentric, involves the recruitment of patients who have presented themselves to the U.O. of Gynecology and Pathophysiology of Human Reproduction in the time interval between 2011 and 2020 in condition of amenorrhea above 6 months, Aged between 15 and 39 at the time of first visit. Patients will be asked to participate in this study during the outpatient follow-up visit.

The study will involve data collection through consultation of health records.

Eligibility criteria

Inclusion criteria:

  • Patients who have presented themselves to the O.U. of Gynecology and Human Reproduction Pathophysiology in the period from 2011 to 2020 with amenorrhea over 6 months, and aged between 15 and 39 years at the time of the visit.
  • Patients who have reached the age of 18 at the time of surgery.
  • Patients for whom has been obtained.

Exclusion criteria: No exclusion criteria are provided.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
180 participants (estimated)
Patient registry
No

Groups and cohorts

  • GROUP A

    Natural estrogen (estradiol or valerate estradiol) administered transdermically

  • GROUP B

    Natural estrogen administered orally

  • GROUP C

    Etinil-estradiol administered orally

  • GROUP D

    No therapy

06

What researchers measure

Primary outcomes

  1. Primary Outcome Measure

    The objectives of the study will be achieved by analysing the following parameters: Collection of anamnestic (eating habits and sports, pathologies of importance, medication intake, previous surgical interventions, smoking habit, gynecological history).

    Time frame: Until the end of the study (1 year)

  2. Primary Outcome Measure

    The objectives of the study will be achieved by analysing the following parameters: Physical examination: calculation of BMI (weight Kg/(height meters \* height in meters), blood pressure (mm Hg)

    Time frame: Until the end of the study (1 year)

  3. Primary Outcome Measure

    The objectives of the study will be achieved by analysing the following parameters: Transvaginal or transabdominal pelvic ultrasound (Uterus measures mm; endometrium thickness mm; ovary size volume cc and mesures mm)

    Time frame: Until the end of the study (1 year)

  4. Primary Outcome Measure

    The objectives of the study will be achieved by analysing the following parameters: Lumbar, femoral, total body dual-energy x-ray absorptiometry (DXA): BMD (g/cm2); T score e Z score.

    Time frame: Until the end of the study (1 year)

  5. Primary Outcome Measure

    Blood tests: hemoglobin (g/gl), hematocrit (%),red blood cells (million/µl), Platelets (x1000/ µl), Glucose (mg/dl), Alt (U/L), Ast (U/L), triglycerides (mg/dl), Total cholesterol (mg/dl), HDL Cholesterol (mg/dl), LH (mU/ml), FSH (mU/ml), Testosteron (ng/ml), Proladctin ( ng/ml), Estradiol (pg/ml); Urinalysis: PH, proteins(mg/dl) Glucose (mg/dl), Red blood cells (num/microL), Leukocytes

    Time frame: Until the end of the study (1 year)

Secondary outcomes

  1. GAGs and Ferriman Score

    For Acne: The GAGS divides the face (forehead, each cheek, nose, and chin), chest, and back into six areas, and the severity in each zone is then assessed on a scale of 0 to 4 (0, no lesions; 1, comedones; 2, papules; 3, pustules; and 4, nodules.

    Time frame: Until the end of the study (1 year)

  2. GAGs and Ferriman Score

    For Hirsutism: The Ferriman-Gallwey is widely used to evaluate and quantify hirsutism in women. The method incorporates nine body regions (excludes legs and forearms) for the assessment of hair growth, rated from 0 (no growth of terminal hair) to 4 (extensive hair growth) in each of the nine locations. The total score therefore can range from 0 to 36 and a score of \> 8 is considered a sign of androgen excess in Caucasian women. A score of 8 -15 indicates mild hirsutism and \>15 indicates moderate or severe hirsutism. For other ethnic groups, the amount of hair expected for that ethnicity should be considered.

    Time frame: Until the end of the study (1 year)

07

Study locations

1 of 1 sites recruiting
  • IRCCS Azienda Ospedaliero -Univeristaria di Bologna
    Bologna, 40138, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2020 (actual). Primary completion is estimated for Oct 2025, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2024
First posted
Jun 11, 2025
StartActual
Nov 9, 2020
Primary completionEst.
Oct 2025
CompletionEst.
Nov 2026
Last update
Jun 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07015476
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Nov 9, 2020
Primary completion
Oct 2025 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jun 11, 2025

Study contacts

Maria C Meriggiola, MD
Contact
cristina.meriggiola@unibo.it
0512144394 ext. +39
Maria C Meriggiola, MD
principal investigator · IRCCS Azienda Ospedaliero-Universitaria di Bologna

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion